Pear Therapeutics, a Boston, MA- and San Francisco, CA-based creator of prescription pharmaceutical-software combination products called eFormulations, closed on additional financing of undisclosed amount.
The round was led by 5AM Ventures, with participation from additional investors. In conjunction with the funding, Andrew J. Schwab, Founding Managing Partner of 5AM Ventures, joined Pear Therapeutics’ Board of Directors.
The company intends to use the funds to build a portfolio of eFormulationsTM.
Led by Corey McCann, President and CEO, Pear is developing digital health interventions to enhance the efficacy of pharmaceutical preparations. The company’s eFormulationTM platform combines pharmaceutical preparations with customizable, and scientifically validated software applications.
It is initially focused on disorders of the brain.